Українська English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2020; 66(5): 55-63


L.V. Natrus, D.V. Maltsev, Yu.G. Klys, T.I. Panova, V.E. Kondratiuk, S.E.Konovalov

    Bogomoletz National Medical University, Kyiv, Ukraine


The correlations between cytokine status, vascular endothelial growth factor (VEGF) content, clinical and biochemical parameters in patients with various forms of gout were studied to improve the algorithm for monitoring of clinical condition and effectiveness of treatment. For patients with gout and volunteers clinical and biochemical studies were performed. The content of interleukins (IL-1β, IL-17, IL-22, IL-10), tumor necrosis factor alpha (TNF-α) and VEGF were investigated. Concentrations of TNF-α, IL-1β and IL-17 characterized of inflammation intensity at all stages of gout and increased linearly as the disease progressed. At the stage of asymptomatic hyperuricemia, there were an increased (75% of the control group) concentration of IL-22 on the background of lymphopenia, low concentrations of IL-10 and VEGF. This indicates that the content of IL-22 is a potentially informative biomarker of inflammation intensity as well as a possible predictor of the development of immune-dependent complications and vascular catastrophes in the early stages of gout without signs of joint damage. The concentration of TNF-α positively correlates with the content of IL-10 (r = 0.534); whereas the concentration of IL-1β is independent of the content of IL-10. The relationship between IL-1β and VEGF concentrations (r = 0.40) suggests that IL-1β is more closely associated with endothelial dysfunction and the risk of vascular complications. IL-22 levels do not correlate with other cytokine status, but are associated with lymphocyte counts, so signs of Th22-dependent immune inflammation may be a potential biomarker of lymphocytic depression status in gout. Cytokine status changes in different phases and stages of hyperuricemia. Comparing these changes with the clinical and laboratory picture improves monitoring of the disease development and effectiveness of treatment.

Keywords: stages of gout, inflammation, cytokines, vascular complications.


  1. Amaral FA, Bastos LF, Oliveira TH, et al. Transmembrane FNO-α is sufficient for articular inflammation and hypernociception in a mouse model of gout. Eur J Immunol. 2016;46(1):204-11. CrossRef PubMed
  2. Busso N, So A. Mechanisms of inflammation in gout. Arthritis Res Ther. 2010; 12(2):206. CrossRef PubMed PubMedCentral
  3. Maltsev DV, Natrus LV, Kondratiuk VYe, Degtyarova IE. Immunological aspects of pathogenesis of gout in light of recent scientific discoveries as a key for development of informative biomarkers and innovative therapeutic strategies Biol Stud. 2018;12(3-4):103-16. CrossRef
  4. Hao G, Duan W, Sun J, Liu J, Peng B. Effects of febuxostat on serum cytokines IL-1, IL-4, IL-6, IL-8, FNO-α and COX-2. Exp Ther Med. 2019;17(1):812-6. CrossRef
  5. Webb R, Jeffries M, Sawalha AH. Uric acid directly promotes human T-cell activation. Am J Med Sci. 2009;337(1):23-7. CrossRef PubMed
  6. Martin WJ, Walton M, Harper J. Resident macrophages initiating and driving inflammation in a monosodium urate monohydrate crystal-induced murine peritoneal model of acute gout. Arthritis Rheum. 2009;60(1):281-9. CrossRef PubMed
  7. Dang W, Xu D, Xie W, Zhou J. Study on the expressions of NLRP3 gene transcript variants in peripheral blood monocytes of primary gout patients. Clin Rheumatol. 2018;37(9):2547-55. CrossRef PubMed
  8. Cavalcanti NG, Marques CD, Lins E, Pereira MC. Cytokine profile in gout: Inflammation driven by IL-6 and IL-18? Immunol Invest. 2016;45(5):383-95. CrossRef PubMed
  9. Zhang QB, Qing YF, Yin CC, et al. Mice with miR-146a deficiency develop severe gouty arthritis via dysregulation of TRAF 6, IRAK 1 and NALP3 inflammasome. Arthritis Res Ther. 2018;20(1):45. CrossRef PubMed PubMedCentral
  10. Liu-Bryan R. Intracellular innate immunity in gouty arthritis: role of NALP3 inflammasome. Immunol Cell Biol. 2010;88(1):20-3. CrossRef PubMed PubMedCentral
  11. Estevez-Garcia IO, Gallegos-Nava S, Vera-Pérez E, et al. Levels of cytokines and microRNAs in individuals with asymptomatic hyperuricemia and ultrasonographic findings of gout: a bench-to-bedside approach. Arthritis Care Res (Hoboken). 2018;70(12):1814-21. CrossRef PubMed
  12. Conforti-Andreoni C, Spreafico R, Qian HL, et al. Uric acid-driven Th17 differentiation requires inflammasomederived IL-1 and IL-18. J Immunol. 2011;187:5842-50. CrossRef PubMed
  13. Liu Y, Zhao Q, Yin Y, McNutt MA, Zhang T, Cao Y. Serum levels of IL-17 are elevated in patients with acute gouty arthritis. Biochem Biophys Res Commun. 2018;497(3):897-902. CrossRef PubMed
  14. Luo G, Yi T, Zhang G, Guo X, Jiang X. Increased circulating Th22 cells in patients with acute gouty arthritis: A CONSORT-compliant article. Medicine (Baltimore). 2017;96(42):e8329. CrossRef PubMed PubMedCentral
  15. Mills KH, Dungan LS, Jones SA, Harris J. The role of inflammasome-derived IL-1 in driving IL-17 responses. J Leukoc Biol. 2013;93(4):489-97. CrossRef PubMed
  16. Masalova EA. Dynamics of indicators of the immune status and rigidity of the vascular wall in patients with gout during therapy with urisan. [Abstract of dissertation]. Kursk: Kursk State Med Univ; 2011. [Russian].

© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2024.